+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
12 Sep 2015

Suven’s neurodegenerative drug got 5 product patents

Suven Life Sciences Ltd (Suven), a Hyderabad-based biopharmaceutical company focussed on discovering, developing and commercialising novel pharmaceutical products, has received five product patents for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

The five granted product patents, one from China (CN 102869647), one from Israel (220709), one from Mexico (329382), one from Singapore (181992) and one from Sri Lanka (15412).

The claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of seventeen (17) granted patents from China, seven (7) granted patents from Israel, twenty (20) granted patents from Mexico, twenty one (21) granted patents from Singapore and eleven (11) granted patents from Sri Lanka. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

Earlier in this month, the company’s new chemical entity (NCE) SUVN-D4010 commenced phase 1 clinical trial in USA.

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!